Isabelle Madelaine

Université Paris Cité — France

Medicine · Health Sciences

30h-index4.2kcitations157works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(27), Lymphoma Diagnosis and Treatment(14), Melanoma and MAPK Pathways(13), Safe Handling of Antineoplastic Drugs(13), Pharmaceutical Practices and Patient Outcomes(12)

Publications153 total

Factors associated with immune-related adverse events in cancer patients treated with immunotherapy visiting the emergency department
The American Journal of Emergency Medicine·2025
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
HemaSphere·2025· 4 citedOpen Access
Randomised controlled trial to assess the impact of hospital–community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs—a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol
BMJ Open·2025Open Access
Predictive factors for delayed high-dose methotrexate elimination: A practical issue for diffuse large B-cell lymphoma patients
Journal of Oncology Pharmacy Practice·2025
The pharmaceutical circuit of Advanced Therapy Medicinal Products—guidelines of the French Society for Oncology Pharmacy
Cytotherapy·2025· 1 citedOpen Access
Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Blood·2024Open Access
JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities
Blood·2024
Prérequis et organisation du parcours de soins en vue de l’utilisation d’une thérapie cellulaire ou génique par cellules stromales mésenchymateuses (CSM) ou par cellules T porteuses d’un récepteur antigénique chimérique (CAR-T cells) chez les patients avec maladies auto-immunes systémiques
Bulletin du Cancer·2024Open Access
Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations
Supportive Care in Cancer·2024Open Access
Évaluation des pratiques professionnelles sur l’utilisation des armoires informatisées de stockage des médicaments par les infirmiers diplômés d’état
Annales Pharmaceutiques Françaises·2024· 1 cited
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs
BioDrugs·2024· 2 citedOpen Access
Réforme de l’accès dérogatoire : impact sur la gestion dans une PUI et identification des risques
Annales Pharmaceutiques Françaises·2024· 1 cited
Metastatic perirectal PEComa treated by checkpoint inhibitor immunotherapy and multimodal treatment: case report and review of the literature
Therapeutic Advances in Medical Oncology·2024· 5 citedOpen Access
OP25 Developments in Anticancer Drugs Preparation Activity in Hospitals Pharmacies Units (HPU) and Their Impact on the Activity of Paris University Hospitals (AP-HP)
Value in Health·2023Open Access
P32 Implementation of Early Access Reform in France and Access to Innovation: Impact in Terms of Number of Drugs, Patients Treated, and Cost
Value in Health·2023
Failure and out of Specification Manufacturing of Autologous CAR-T Cells Could be Associated with a High Concentration of Total Nucleated Cells, CD3 + Cells and Neutrophils in the Apheresis Product
Blood·2023· 7 cited
Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy
Blood·2023· 2 cited
Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022
Bulletin du Cancer·2023· 5 cited
CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
European Journal of Cancer·2023· 1 cited
Toxicités immuno-induites chez les patients avec cancer sous immunothérapie par inhibiteurs des <i>checkpoints</i>. Ce que l’urgentiste doit savoir
Annales françaises de médecine d’urgence·2023· 1 cited
page 1 of 8Next →

Frequent Co-authors

Jean‐Michel Molina(11), Catherine Thiéblemont(11), Célèste Lebbé(10), Sylvie Chevret(8), Jérôme Larghero(7), Laëtitia Vercellino(7), Marie Danet(6), Sophie Caillat‐Zucman(6), M. Bagot(6), Caroline Gatey(5), Élie Azoulay(5), Nicolas Boissel(5), Samia Mourah(5), Roberta Di Blasi(5), Gilles Pialoux(4), Constance Delaugerre(4), Béatrice Berçot(4), Laurent Cotte(4), Claire Pintado(4), Bénédicte Loze(4)